Arcadia Biosciences, Inc.

RKDA Consumer Defensive Packaged Foods

Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.

0.16 0.04 −20.00%
Market cap
$490.0K
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−59.20
Beneish M
−1.84
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
50.56 13.02 21.82 25.33 25.67 28.69 20.64 11.64 4.24 4.56
Receivables
0.53 1.24 0.17 0.60 1.41 1.37 1.22 0.51 1.18 0.43
Inventory
0.25 0.23 0.18 1.79 3.81 4.43 2.32 0.84 0.90 1.21
Other current assets
0.88 0.56 0.70 0.71 0.81 0.90 0.09 0.05 — —
Total current assets
52.22 15.05 22.88 28.44 31.70 35.39 25.40 14.97 9.24 6.36
Property, Plant, Equpment (Net)
0.51 0.30 0.40 1.80 3.54 2.29 0.68 0.07 0.04 0.01
Long-Term Investments
2.50 — — — — — — — — —
Long-term receivables
— — — — — — — — 3.97 —
Goodwill and Intangible Assets (Total)
— — — — 0.78 0.48 0.04 0.04 0.04 0.04
Long-term assets (Other)
0.02 0.06 0.01 0.01 2.02 0.18 0.17 0.16 0.09 0.14
Total non-current assets
4.35 1.52 1.15 4.13 15.65 8.53 3.52 4.73 4.28 0.19
Total Assets
56.57 16.57 24.02 32.57 47.35 43.92 28.92 19.71 13.52 6.55
Accounts Payable
2.36 2.50 2.65 4.69 4.11 3.64 2.86 1.91 2.11 1.79
Current Part of Debt
— — — 0.02 1.14 — — — — —
Current Revenue (Deferred)
0.74 1.00 0.10 0.04 0.01 — — — — —
Other current liabilities
2.88 3.14 0.28 0.31 0.26 0.26 0.27 0.27 0.27 0.27
Total current liabilities
3.13 3.53 3.05 5.71 6.31 5.04 4.21 3.59 2.56 2.06
Long Term Debt (Total)
25.13 — — 0.11 2.11 — — — — —
Non-current Revenue (Deferred)
3.12 2.04 — — — — — — — —
Non-current Liabilities (Other)
3.00 3.00 8.16 16.94 4.99 5.46 2.81 3.26 4.73 0.35
Total non-current liabilities
31.25 5.04 8.16 18.54 12.48 7.68 3.81 3.41 4.73 0.35
Total liabilities
34.38 8.56 11.21 24.25 18.80 12.72 8.02 7.00 7.29 2.41
Additional Paid In Capital
173.72 175.22 191.14 214.83 239.50 257.52 278.83 284.52 285.04 285.29
Common Stock (Net)
0.04 0.04 0.05 0.05 0.05 0.06 0.07 0.07 0.07 0.07
Retained Earnings
(151.55) (167.26) (178.37) (207.17) (211.82) (226.48) (257.86) (271.84) (278.88) (281.22)
Common Equity (Total)
22.20 8.01 12.82 8.33 28.55 31.20 20.90 12.70 6.22 4.14
Shareholders Equity (Total)
22.20 8.01 12.82 8.33 28.55 31.20 20.90 12.70 6.22 4.14
Shareholders Equity and Liabilities (Total)
56.57 16.57 24.02 32.57 47.35 43.92 28.92 19.71 13.52 6.55
Shares (Common)
0.06 0.05 0.12 0.22 0.34 0.56 0.62 1.29 1.37 1.37
Shareholders Equity (Tangible)
22.20 8.01 12.82 8.33 27.77 30.71 20.86 12.66 6.18 4.10
Net Debt
(25.43) (13.02) (21.82) (25.20) (22.42) (28.68) (20.64) (11.64) (4.24) (4.56)
Total Debt
25.13 — — 0.13 3.25 3.29 2.02 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates